Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies - Wikidata - awgldk - TriplyDB

Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies

Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies

http://www.wikidata.org/entity/Q35013856

about

Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients.Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications Alternative pre-approved and novel therapies for the treatment of anthrax Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis A review of linezolid: the first oxazolidinone antibiotic.Probable linezolid-induced thrombocytopenia in a patient with vancomycin-resistant enterococci.Comparative evaluation of thrombocytopenia in adult patients receiving linezolid or glycopeptides in a respiratory intensive care unit.Clinical population pharmacokinetics and toxicodynamics of linezolid.Risk factors for thrombocytopenia in adult chinese patients receiving linezolid therapy.Safety profiles of old and new antimicrobials for the treatment of MRSA infections.Docking studies on novel analogues of 8 methoxy fluoroquinolones against GyrA mutants of Mycobacterium tuberculosis.Linezolid for the treatment of multidrug-resistant tuberculosis.Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer.Risk of serotonin syndrome with concomitant administration of linezolid and serotonin agonists.Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis.Efficacy of the new lantibiotic NAI-107 in experimental infections induced by multidrug-resistant Gram-positive pathogens.Linezolid for the treatment of drug-resistant infections.Update on the safety of linezolid.Clinical update on linezolid in the treatment of Gram-positive bacterial infections.Serotonin toxicity associated with concomitant use of linezolid.Role of linezolid in the treatment of orthopedic infections.Pancytopenia due to linezolid treatment.Update on linezolid: the first oxazolidinone antibiotic.Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.Methicillin-resistant Staphylococcus epidermidis (MRSE) endocarditis treated with linezolid.Linezolid: effectiveness and safety for approved and off-label indications.Update on the appropriate use of linezolid in clinical practice A current perspective on daptomycin for the clinical microbiologist.The oxazolidinones: past, present, and future.Risk factors associated with high linezolid trough plasma concentrations.Front-loaded linezolid regimens result in increased killing and suppression of the accessory gene regulator system of Staphylococcus aureus.Linezolid interaction with serotonin reuptake inhibitors: report of two cases and incidence assessment.Linezolid and serotonin syndrome.Linezolid-induced neuropathy.Successful treatment of Staphylococcus epidermidis prosthetic valve endocarditis with linezolid after failure of treatment with oxacillin, gentamicin, rifampicin, vancomycin, and fusidic acid regimens.Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections.Carrier-free nanoassemblies of a novel oxazolidinone compound FYL-67 display antimicrobial activity on methicillin-resistant Staphylococcus aureus.The in vivo and in vitro phase I metabolism of FYL-67, a novel oxazolidinone antibacterial drug, studied by LC-MS/MS.Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies.Linezolid as rescue treatment for left-sided infective endocarditis: an observational, retrospective, multicenter study.

P2860

Q24542412-131A3AC2-9B1B-46BE-AEAF-04C3EE239F6F Q24646677-7AD8055A-431D-45B0-9648-49E03A19D6B3 Q28075453-28E80737-ADF8-46EF-9069-ED12A25BB229 Q28384759-4D97EBBE-0838-4C4F-B632-03DE01777034 Q33363226-3F551FE5-EE1A-464A-BE8A-08C6EE4581C5 Q33400991-685F6C2D-D6B4-4AEE-A3C6-530B67CC6D1E Q33412500-8698FD9B-1657-4902-AA22-3E214F62BE53 Q33413269-DE66AAF2-ECAD-4896-B6E3-93E21BC9043D Q33414112-0C61F70E-848C-4AEA-BF3F-D1CFC1C5597C Q33429168-556F028C-9676-4796-87EE-56A2CD695C1F Q34094873-037052CB-7017-42DB-A76D-B30A78156CA8 Q34420818-44BD810B-A36C-43CF-8740-E28A713B70BB Q34489730-8AE0B8BF-47E8-4317-9DE3-7AC137901823 Q34584411-1D54B219-5C20-40F5-9184-3E0693C9CE7B Q34728711-8279182B-B5B8-40AE-B932-B4C552069C9E Q34737510-50421B1A-339D-49C5-94CE-2C0E6A393D56 Q34894133-6BCC9832-D1AC-4545-BBF2-7ABC051EA497 Q34987632-F9AF1221-182D-4F3E-A9D3-F3A89E665092 Q36083208-AC71CD04-256E-45B3-B4B1-7DE3D68BEBA9 Q36096723-EA502BA6-6A9D-467B-95A6-F7344B8CDFCE Q36162348-1AD7689B-9500-4B72-903E-C9934B9AD9B6 Q36239836-09E1FD4A-6686-4571-AD11-DC4C1607F60D Q36283744-A1AA45D2-8C8E-4DF3-BDCF-77A61A90B472 Q36718474-978C67D5-859D-4444-825F-9382570F4A20 Q36939685-E3F9481B-D72F-421B-9388-049C85426B5E Q36967288-2F3E6D8A-C17E-4D8D-AA9B-A2FAD4A11612 Q37116859-44CC7C0A-D29E-4B24-9E67-8BC9926E55D0 Q37263289-F8DF479C-3BDC-43EC-8410-FBD3FEAC9169 Q37970719-8468704E-ED0D-452E-A180-D6C501393A81 Q40683242-AF7B70C1-2750-4DA4-869E-044D59D37FE7 Q42110580-57CF60FF-181D-448E-8B84-165C1B265F1F Q42745595-89B7DD1F-FDB4-4AD8-9599-7AE86BC37694 Q42938643-A6C6E13D-A453-4FB5-A8E0-E8809FDFDC8B Q44778124-3D61A6E4-D554-4444-9B19-11D2406CEFC5 Q45129556-845DFEAD-6200-4ABA-B29F-C5C058A9EE34 Q45230598-EBED5706-4937-41A4-9359-4F2906222863 Q45811171-3216B11A-1967-4343-A2FF-610EBAB1DCFE Q46653380-1AF7083D-2143-4E30-8410-00748AFDE54D Q46728767-2371C0C6-C328-4C9B-B5F9-46C8F70C3ED1 Q48002727-DB1D1A13-FB6F-4303-AEF6-1FC07B3EA9BD

P2860

Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies

http://www.wikidata.org/entity/Q35013856

description

2003 nî lūn-bûn

@nan

2003 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Worldwide assessment of linezo ...... r-controlled phase III studies

@ast

Worldwide assessment of linezo ...... r-controlled phase III studies

@en

type

label

Worldwide assessment of linezo ...... r-controlled phase III studies

@ast

Worldwide assessment of linezo ...... r-controlled phase III studies

@en

prefLabel

Worldwide assessment of linezo ...... r-controlled phase III studies

@ast

Worldwide assessment of linezo ...... r-controlled phase III studies

@en

P1433

Q35013856-866CAA57-7E46-4DE3-A71C-839B598EEBF2

P1476

Q35013856-20D40390-C340-4685-8F68-862204D45E62

P2093

Q35013856-2329410D-B093-4A90-A495-93E76D5B4BE4

Q35013856-40FB61B3-746A-466D-839E-1F01BEC99E7F

Q35013856-43496D06-5DF2-41D8-94C7-04D3963F0861

Q35013856-4F3E891E-3342-4AF6-B024-697961900610

Q35013856-8FB99BBA-9A39-445F-896B-A3A84A47625A

Q35013856-A1DF16C8-C637-47A5-A399-40E3449887C1

Q35013856-D155C75D-1066-4079-86D8-2DDFA83D4953

Q35013856-D30BA305-73F8-470E-9AF6-C23D4D6B8B5D

Q35013856-FF9C12DD-A3D8-4678-95A8-080E08A8383F

P2860

Q35013856-01135C89-6065-458D-B162-D75FF6BAC177

Q35013856-175A173E-D10B-4017-A73A-C3E8E78C20B5

Q35013856-1D4579F2-16F2-414D-B7F8-8BBDA47E67BB

Q35013856-240D59FC-73BB-4C07-9621-5E0058D85876

Q35013856-240F7314-6227-4C30-A8B4-792ADC8072EC

Q35013856-46D71498-CA47-4A1A-BF19-8E887A8DA720

Q35013856-498DCB35-757C-465F-8BF9-54B08C8FEDE0

Q35013856-514AD18D-B5CE-4959-AF2D-D2ECBE5F811A

Q35013856-649E62D2-8542-49EF-9D02-4AD7A7133EAA

Q35013856-668E703E-ADE0-491A-A484-12626C0FB692

P304

Q35013856-24D4BE00-7EBB-45D8-9D2D-2CA24E6FC4A9

P31

Q35013856-E61C5B9F-603D-4F8D-B560-53D3047D23E7

P356

Q35013856-48FE9C5A-9703-4336-A635-ED5BC16F04A2

P407

Q35013856-4E38CF94-4471-48AA-975C-BFC97A5E600A

P433

Q35013856-5A1A3676-87DA-4CD3-88A1-9E601F0BCDF5

P478

Q35013856-1E1F4E6D-6DA9-497E-9509-B2A37D70F19A

P577

Q35013856-991BDBFD-2EB8-4A35-81B9-87648C3DA74E

P698

Q35013856-031F269E-641D-4E50-92F0-799ADCE55DAB

P932

Q35013856-3083C97A-E2A3-45D5-9D51-A868C08AD4E9

P356

AAC.47.6.1824-1831.2003

P1433

Antimicrobial Agents and Chemotherapy

P1476

Worldwide assessment of linezo ...... r-controlled phase III studies

@en

P2093

Barry Hafkin

http://www.w3.org/2001/XMLSchema#string

Ethan Rubinstein

http://www.w3.org/2001/XMLSchema#string

Harold C Standiford

http://www.w3.org/2001/XMLSchema#string

Jack Remington

http://www.w3.org/2001/XMLSchema#string

Leon G Smith

http://www.w3.org/2001/XMLSchema#string

Raul Isturiz

http://www.w3.org/2001/XMLSchema#string

Sue Cammarata

http://www.w3.org/2001/XMLSchema#string

Thomas H Oliphant

http://www.w3.org/2001/XMLSchema#string

Vu Le

http://www.w3.org/2001/XMLSchema#string

P2860

The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria

Cephalosporin-induced hemolysis: a case report and review of the literature

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study.

Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid.

Linezolid-Induced anemia and thrombocytopenia.

Thrombocytopenia associated with linezolid therapy.

Hematologic effects of linezolid: summary of clinical experience.

Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program.

Haematological adverse drug reactions in hospital practice.

P304

1824-1831

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.47.6.1824-1831.2003

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

2003-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12760854

http://www.w3.org/2001/XMLSchema#string

P932

155822

http://www.w3.org/2001/XMLSchema#string